Diagnosis of mast cell activation syndrome: a global “consensus-2”
Authors:
- Lawrence B. AfrinLALawrence B. Afrin
- Linda S. BluesteinLBLinda S. Bluestein
- Joseph H. BrewerJBJoseph H. Brewer
- Jill B. BrookJBJill B. Brook
- Ariana D. BuchananABAriana D. Buchanan
- Jill R. CuniJCJill R. Cuni
- William P. DaveyWDWilliam P. Davey
- Tania T. DempseyTDTania T. Dempsey
- Shanda R. DorffSDShanda R. Dorff
- Alena G. GuggenheimAGAlena G. Guggenheim
Open Access
- 9 April 2020
- journal article
- review article
- Published by Walter de Gruyter GmbH in Diagnosis
- Vol. 8 (2) , 137-152
Abstract
The concept that disease rooted principally in chronic aberrant constitutive and reactive activation of mast cells (MCs), without the gross MC neoplasia in mastocytosis, first emerged in the 1980s, but only in the last decade has recognition of “mast cell activation syndrome” (MCAS) grown significantly. Two principal proposals for diagnostic criteria have emerged. One, originally published in 2012, is labeled by its authors as a “consensus” (re-termed here as “consensus-1”). Another sizable contingent of investigators and practitioners favor a different approach (originally published in 2011, newly termed here as “consensus-2”), resembling “consensus-1” in some respects but differing in others, leading to substantial differences between these proposals in the numbers of patients qualifying for diagnosis (and thus treatment). Overdiagnosis by “consensus-2” criteria has potential to be problematic, but underdiagnosis by “consensus-1” criteria seems the far larger problem given (1) increasing appreciation that MCAS is prevalent (up to 17% of the general population), and (2) most MCAS patients, regardless of illness duration prior to diagnosis, can eventually identify treatment yielding sustained improvement. We analyze these proposals (and others) and suggest that, until careful research provides more definitive answers, diagnosis by either proposal is valid, reasonable, and helpful.Keywords
This publication has 88 references indexed in Scilit:
- Familial Occurrence of Systemic Mast Cell Activation DiseasePLOS ONE, 2013
- Regulation of the immune response and inflammation by histamine and histamine receptorsJournal of Allergy and Clinical Immunology, 2011
- Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus ProposalInternational Archives of Allergy and Immunology, 2011
- FcεRI, but Not FcγR, Signals Induce Prostaglandin D2 and E2 Production from BasophilsThe American Journal of Pathology, 2011
- Expression of Prostaglandin E Synthases in PeriodontitisThe American Journal of Pathology, 2011
- Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic optionsJournal of Hematology & Oncology, 2011
- Catestatin, a neuroendocrine antimicrobial peptide, induces human mast cell migration, degranulation and production of cytokines and chemokinesImmunology, 2011
- IgE, mast cells, basophils, and eosinophilsJournal of Allergy and Clinical Immunology, 2010
- Characterization of gene expression profiles for different types of mast cells pooled from mouse stomach subregions by an RNA amplification methodBMC Genomics, 2009
- Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxisBlood, 2007